Cerebrolysin
A mixture of brain-derived neurotrophic peptides used clinically in over 50 countries for stroke, TBI, and dementia. Cerebrolysin is one of the few neuropeptide treatments with actual clinical trial data — though it remains controversial in Western neurology.
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and amino acids derived from pig brain tissue. It mimics the action of neurotrophic factors like BDNF and NGF, promoting neuronal survival, synaptogenesis, and neuroplasticity. It's been used clinically for decades in Europe, Asia, and Russia for stroke recovery, traumatic brain injury, and dementia.
Who's interested: People recovering from stroke or TBI, those with early dementia, and biohackers interested in clinical-grade neuroprotection.
Dive deeper into the researchPotential side effects
- Injection site reactions and discomfort
- Dizziness and mild agitation (uncommon)
- Animal-derived product — allergic reactions possible
What does Cerebrolysin do?
Your brain's ability to repair itself depends on neurotrophic factors — proteins like BDNF and NGF that promote neuronal survival, growth, and connection formation. After brain injury (stroke, TBI), these factors are critical for recovery.
Cerebrolysin provides a cocktail of neurotrophic peptide fragments that cross the blood-brain barrier and mimic the effects of BDNF, NGF, and other growth factors. The theory: by flooding the brain with these repair signals, you can enhance neuroplasticity and recovery after injury.
Who uses it?
- Stroke recovery — the most studied indication; clinical trials in acute and subacute stroke
- Traumatic brain injury — used in clinical settings for TBI rehabilitation
- Dementia / Alzheimer's — some clinical trial data showing modest cognitive improvements
- Cognitive enhancement — biohackers using it for nootropic purposes
- Pediatric neurology — used in some countries for cerebral palsy and autism (controversial)
What to know before trying
Cerebrolysin occupies an unusual position: widely used clinically in Europe/Asia/Russia, with multiple RCTs, but viewed skeptically by many Western neurologists who consider the evidence insufficient for major guideline inclusion.
- Large-volume injections — clinical doses require 10–30 mL IV, typically given in medical settings
- Manufactured by EVER Pharma — a legitimate pharmaceutical company, not a grey-market peptide
- Animal-derived — processed from porcine (pig) brain tissue
- Course-based treatment — typically given daily for 10–20 days in clinical protocols
Tracking a peptide protocol?
eterni connects your labs, supplements, and retests — so you can see whether your protocol is actually working.
Get early accessFrequently Asked Questions
What is Cerebrolysin made from?
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine (pig) brain tissue through a standardised enzymatic breakdown process. It is manufactured by EVER Pharma (Austria) and has been used clinically since the 1970s.
Does Cerebrolysin work for stroke recovery?
Multiple RCTs show improvements in neurological outcomes when Cerebrolysin is given within the first 72 hours of acute ischemic stroke. A 2020 Cochrane review found modest evidence of benefit but noted study quality limitations. It is included in stroke guidelines in some countries but not in US/UK guidelines.
Is Cerebrolysin available in India?
Cerebrolysin is available in India through specialty neurological clinics and can be prescribed by physicians. It is also obtainable through international pharmaceutical importers. It is a legitimate manufactured drug, not a grey-market peptide.
Can I use Cerebrolysin for cognitive enhancement?
Some biohackers use lower doses (5–10 mL IM) for nootropic purposes. Anecdotal reports suggest improved mental clarity, focus, and verbal fluency. However, no clinical trials have tested Cerebrolysin specifically for cognitive enhancement in healthy individuals.
How it works
- Neurotrophic factor mimicry — peptide fragments act like BDNF, NGF, CNTF, and GDNF
- BBB penetration — low molecular weight allows crossing the blood-brain barrier
- Neuroplasticity — promotes synaptogenesis, dendritic branching, and neuronal survival
- Anti-apoptotic — protects neurons from programmed cell death after injury
- Anti-inflammatory — reduces neuroinflammation that worsens brain injury outcomes
Clinical evidence
- Acute stroke (CASTA trial): 1,070-patient RCT showed trend toward improved outcomes; significant benefit in moderate-severe strokes
- TBI: Phase III data showing improved Glasgow Outcome Scale scores
- Alzheimer's: Modest improvements in ADAS-cog scores over 6 months in some trials
- Cochrane review (2020): "Low to moderate quality evidence" of benefit in acute ischemic stroke
Side effects & safety
- Injection site pain — especially with IM administration of larger volumes
- Dizziness — reported in some clinical trial participants
- Agitation/restlessness — uncommon; may relate to neurotrophic stimulation
- Allergic reactions — possible due to animal-derived origin; rare
- Generally well-tolerated — decades of clinical use with a reasonable safety record
Who should avoid it: People allergic to pork products, those with epilepsy (theoretical seizure threshold concern), and people with severe renal impairment.
Know what's working. Know what's not.
eterni connects your lab results, supplements, and retests — so you can see the trajectory, not just a snapshot.
Join the waitlist